EMA
withdrawal
· 2008-01-24
EMA Refused: Mylotarg (gemtuzumab ozogamicin) — Wyeth Europa Ltd
Summary
The EMA refused approval for Mylotarg (gemtuzumab ozogamicin) by Wyeth Europa Ltd for acute myeloid leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Refused. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Wyeth Europa Ltd. Decision date: 24/01/2008. Orphan medicine